SecBot SecBot
Biotech Drug Report Generated Nov 4, 2026

Xtandi

PFE·PFIZER INC
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and marketed since 2012. The next inflection point is the US patent expiry in August 2027, which will allow generic competition.
Why 4/10
Xtandi is an already-approved, marketed drug with no pending PDUFA date or pivotal readout in the next ~12 months. The next hard catalyst is the US patent expiry in August 2027, which is a known commercial headwind rather than a binary regulatory event. For Pfizer, Xtandi is one of many products in a ~$62B+ revenue portfolio, so even a major label decision would move the stock modestly. ImpactScore 4 reflects an approved drug with no imminent binary catalyst.
Actionable Insight NEUTRAL

The next major event for Xtandi is the US composition-of-matter patent expiry in August 2027, which opens the door to generic competition and will pressure revenue. In the nearer term, watch for Pfizer's Q4 2026 earnings (early Feb 2027) for Xtandi sales trends and any update on the talazoparib combo uptake. The ENZARAD trial failure in high-risk localized prostate cancer removes one expansion opportunity.

Price Chart

Loading chart...

Executive Summary

Xtandi (enzalutamide) is a blockbuster oral androgen receptor inhibitor for prostate cancer, co-developed and co-marketed by Pfizer (NYSE: PFE) and Astellas. First approved by the FDA in 2012, it now holds four approved indications spanning metastatic and non-metastatic, castration-resistant and castration-sensitive prostate cancer. Global sales reached approximately $6 billion in Astellas' FY2025, but the franchise faces a major patent cliff: the core US composition-of-matter patent expires in August 2027. On October 26, 2026, the FDA approved a talazoparib (Talzenna) plus Xtandi combination for HRR-mutated metastatic prostate cancer based on the TALAPRO-3 trial. However, the Phase 3 ENZARAD trial (published October 2026) failed to show a benefit in high-risk localized prostate cancer. For Pfizer, Xtandi is a meaningful but non-dominant product within a diversified ~$62B+ revenue portfolio, and the stock's primary drivers extend well beyond this single drug.

How It Works

Xtandi is an androgen receptor inhibitor. It works by blocking the effects of male hormones (androgens like testosterone) on prostate cancer cells. Since prostate cancer cells need androgens to grow, blocking them can slow or stop the cancer's progression. It is taken as a daily oral pill.

Trial Status

Xtandi is FDA-approved across four prostate cancer indications. The most recent approval (October 26, 2026) was for talazoparib plus enzalutamide in HRR-mutated metastatic hormone-sensitive prostate cancer, supported by the Phase 3 TALAPRO-3 trial. The Phase 3 ENZARAD trial in high-risk localized prostate cancer failed to meet its primary endpoint (metastasis-free survival, HR 0.88, p=0.34).

The Two-Sided Case

▲ Bull Case4
Xtandi is a well-established blockbuster with four FDA-approved indications across the prostate cancer treatment continuum, generating ~$6B in global sales (Astellas FY2025).
On October 26, 2026, the FDA approved talazoparib (Talzenna) in combination with Xtandi for HRR-mutated metastatic hormone-sensitive prostate cancer based on the TALAPRO-3 trial, which showed a 52% reduction in risk of progression or death, extending the franchise's utility.
Pfizer's Q3 2026 earnings (reported Nov 3, 2026) beat consensus, and the company raised full-year 2026 guidance, reflecting momentum across its portfolio including oncology.
Despite the looming patent cliff, Astellas and Pfizer continue to defend the franchise with formulation patents extending to 2037 and ongoing lifecycle management.
▼ Bear Case4
Core US composition-of-matter patent expires August 13, 2027, opening the door to generic enzalutamide and a steep revenue decline (Astellas projects a 5.3% drop in FY2026 already).
The Phase 3 ENZARAD trial (published October 2026) showed enzalutamide failed to improve metastasis-free survival in high-risk localized prostate cancer (HR 0.88, p=0.34), closing off a potential label expansion.
Xtandi faces intense competition from J&J's Erleada (apalutamide), Bayer's Nubeqa (darolutamide), and generic abiraterone, all targeting overlapping prostate cancer indications.
For Pfizer, Xtandi is a partnered product (50/50 US profit split with Astellas), so the revenue contribution to Pfizer is only a fraction of the ~$6B global sales figure.

Upcoming Catalysts

  • US composition-of-matter patent expiry on August 13, 2027, which will permit generic enzalutamide entry.
  • Pfizer Q4 2026 earnings (expected early February 2027) for Xtandi sales trends and talazoparib combo uptake.
  • Potential label expansion decisions in ex-US markets for the talazoparib + enzalutamide combination.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PFIZER INC 8-K PFE ·Originating report

Sources · 10

Hover a chip for the title
1 drugs.com2 pfizer.com3 fda.gov4 fiercepharma.com5 patent-analytics.thechemsolver.com6 oncologytube.com7 cnbc.com8 pfizer.com9 newsroom.astellas.com10 fiercepharma.com